Brain Metastasis - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 148 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Brain Metastasis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Brain Metastasis - Pipeline Review, H2 2014', provides an overview of the Brain Metastasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Metastasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Brain Metastasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Brain Metastasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Brain Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Brain Metastasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Brain Metastasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Brain Metastasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Brain Metastasis Overview 9
Therapeutics Development 10
Pipeline Products for Brain Metastasis - Overview 10
Pipeline Products for Brain Metastasis - Comparative Analysis 11
Brain Metastasis - Therapeutics under Development by Companies 12
Brain Metastasis - Therapeutics under Investigation by Universities/Institutes 14
Brain Metastasis - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Brain Metastasis - Products under Development by Companies 18
Brain Metastasis - Products under Investigation by Universities/Institutes 19
Brain Metastasis - Companies Involved in Therapeutics Development 20
Bristol-Myers Squibb Company 20
F. Hoffmann-La Roche Ltd. 21
Sanofi 22
GlaxoSmithKline plc 23
Eisai Co., Ltd. 24
Pfizer Inc. 25
Exelixis, Inc. 26
Nanobiotix 27
Spectrum Pharmaceuticals, Inc. 28
Philogen S.p.A. 29
Nerviano Medical Sciences 30
AngioChem Inc. 31
Diffusion Pharmaceuticals LLC 32
to-BBB technologies BV 33
biOasis Technologies Inc. 34
Phosplatin Therapeutics 35
Sagetis Biotech, S.L. 36
Puma Biotechnology, Inc. 37
AbbVie Inc. 38
Brain Metastasis - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Mechanism of Action 44
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
trastuzumab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ipilimumab - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
neratinib - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
dacomitinib - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
cabozantinib s-malate - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
lucanthone hydrochloride - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
ANG-1005 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
lapatinib ditosylate - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
veliparib - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
2B3-101 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
dabrafenib mesylate - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
cabazitaxel - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
radretumab - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
RAD-1901 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
transcrocetinate sodium - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
PB-357 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
PT-112 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Recombinant Adenoviral Human p53 Gene Therapy - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
BT-2111 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
ANG-4043 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
NBTX-IV - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
NMSE-973 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
SAG-002 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
SAG-003 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Drug for Brain Metastasis - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Brain Metastasis - Recent Pipeline Updates 97
Brain Metastasis - Dormant Projects 137
Brain Metastasis - Discontinued Products 138
Brain Metastasis - Product Development Milestones 139
Featured News & Press Releases 139
Nov 12, 2013: Study Demonstrates biOasis Technologies' Conjugate of Metastatic Cancer Drug, Herceptin, Penetrates Blood-Tumor Barrier 10 Times Greater Than Herceptin Alone 139
Oct 08, 2013: Angiochem to Present at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 139
Jul 29, 2013: Nerviano Medical Sciences researchers report data on a novel molecule inhibitor of HSP90 140
Jun 26, 2013: Nanobiotix Announces Selection Of Its Second NanoXray Product NBTX-IV And Collaboration With National Cancer Institute For Development 140
Apr 09, 2013: biOasis Provides Update On BT2111-Herceptin Program 141
Dec 03, 2012: Geron Discontinues Development Of Brain Cancer Drug Candidate GRN1005 141
Dec 22, 2011: Geron Initiates Phase II Trial Of GRN1005 In Brain Metastases Arising From Lung Cancer 142
Nov 15, 2011: Geron Presents Final Phase I Clinical Data On GRN1005 At AACR-NCI-EORTC 143
Jun 27, 2011: to-BBB Starts Clinical Trial In Patients With Brain Metastases 145
Jun 07, 2010: Angiochem Presents Complete Phase I/II Clinical Data Of ANG1005 For Treatment Of Brain Metastases 145
Appendix 147
Methodology 147
Coverage 147
Secondary Research 147
Primary Research 147
Expert Panel Validation 147
Contact Us 148
Disclaimer 148

List of Tables
Number of Products under Development for Brain Metastasis, H2 2014 10
Number of Products under Development for Brain Metastasis - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Brain Metastasis - Pipeline by Bristol-Myers Squibb Company, H2 2014 20
Brain Metastasis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 21
Brain Metastasis - Pipeline by Sanofi, H2 2014 22
Brain Metastasis - Pipeline by GlaxoSmithKline plc, H2 2014 23
Brain Metastasis - Pipeline by Eisai Co., Ltd., H2 2014 24
Brain Metastasis - Pipeline by Pfizer Inc., H2 2014 25
Brain Metastasis - Pipeline by Exelixis, Inc., H2 2014 26
Brain Metastasis - Pipeline by Nanobiotix, H2 2014 27
Brain Metastasis - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 28
Brain Metastasis - Pipeline by Philogen S.p.A., H2 2014 29
Brain Metastasis - Pipeline by Nerviano Medical Sciences, H2 2014 30
Brain Metastasis - Pipeline by AngioChem Inc., H2 2014 31
Brain Metastasis - Pipeline by Diffusion Pharmaceuticals LLC, H2 2014 32
Brain Metastasis - Pipeline by to-BBB technologies BV, H2 2014 33
Brain Metastasis - Pipeline by biOasis Technologies Inc., H2 2014 34
Brain Metastasis - Pipeline by Phosplatin Therapeutics, H2 2014 35
Brain Metastasis - Pipeline by Sagetis Biotech, S.L., H2 2014 36
Brain Metastasis - Pipeline by Puma Biotechnology, Inc., H2 2014 37
Brain Metastasis - Pipeline by AbbVie Inc., H2 2014 38
Assessment by Monotherapy Products, H2 2014 39
Assessment by Combination Products, H2 2014 40
Number of Products by Stage and Target, H2 2014 43
Number of Products by Stage and Mechanism of Action, H2 2014 46
Number of Products by Stage and Route of Administration, H2 2014 48
Number of Products by Stage and Molecule Type, H2 2014 50
Brain Metastasis Therapeutics - Recent Pipeline Updates, H2 2014 97
Brain Metastasis - Dormant Projects, H2 2014 137
Brain Metastasis - Discontinued Products, H2 2014 138